About Oncotest
Leading the Genomic Revolution in Personalized Medicine
Oncotest brings the world’s most advanced genomic tests to Israel, enabling early cancer detection and precise treatment at every stage of the disease. We are committed to making cutting-edge technologies accessible through partnerships with leading global laboratories while developing advanced local genomic diagnostic capabilities.
About
Oncotest is Israel’s first and leading company in personalized medicine. Since our founding in 1998, we have been committed to providing genomic and genetic testing that enables more precise and effective cancer treatment. We offer a wide range of tests—from early detection to personalized therapy at all stages of the disease.
We collaborate with leading global laboratories, and in recent years, we have invested in bringing genomic expertise to Israel. This allows advanced genomic testing to be performed in molecular pathology institutes across the country, strengthening local diagnostic capabilities and expanding access to cutting-edge technologies.
Over the past two decades, we have played a key role in driving the adoption of genomic testing in Israel. We are proud to be the preferred choice for patients and healthcare professionals seeking advanced genomic solutions.
Our Journey
With a rich history of innovation, we are proud to lead the field of cancer diagnostics and personalized medicine in Israel.
A Vision for the Patient
Dr. Lior Soussan Gutman founded Oncotest, believing every patient deserves the most precise treatment through advanced genetic diagnostics.
Growth and Partnership
Joining the Teva Pharmaceutical Group strengthened our position as leaders in genetic diagnostics.
A Revolution in Breast Cancer Diagnostics
We introduced the Oncotype DX Breast test to Israel and led its adoption among oncologists, resulting in full coverage by health insurance funds.
Advanced Genomic Diagnostics
First in Israel to introduce NGS-based comprehensive profiling, enabling targeted therapy for various cancers.
Liquid Biopsy
Launched Guardant360, an innovative genomic test based on liquid biopsy.
Accessibility for All Patients
Signed agreements with private insurance companies, ensuring funding for genomic tests for many patients.
Expansion and Innovation
Merged with Rhenium, supporting local pathology labs in performing local genomic tests in hous and successfully integrating these tests into the national health basket for full reimbursment.
A Revolution in Early Detection
Launched the Galleri test for the early detection of 50 types of cancer, pioneering the movement for early diagnosis and cancer prevention.
Our Services
Multi Cancer Early Detection blood test
To identify more than
50 cancer types
Hereditary Cancer
Risk
Comprehensive Genetic Testing Through Whole Genome Sequencing
Tailored Genomic Testing for Targeted Treatment
Genomic tests for cancer patients to match targeted treatments across all stages of the disease
Our Commitment
Innovation
We are committed to making the most advanced technologies in the field of genetic diagnostics accessible.
Collaborations
We collaborate with leading laboratories worldwide to ensure the quality of our tests and services.
Professionalism
Our team of experts includes doctors, geneticists, and molecular biologists with extensive experience.
Service
We provide personal guidance and support to every patient throughout the diagnosis and treatment process.
Our Vision
We strive to be the first choice for physicians and patients in the field of personalized medicine in Israel.
Our goal is to lead the field of personalized medicine, accompany you from the moment of discovery and diagnosis to the adaptation of treatment at all stages of the disease, and collaborate with the most advanced companies and laboratories in the world.
Our Story
Dr. Soussan-Gutman founded Oncotest after completing a postdoctoral fellowship at the Weizmann Institute in Biology, focusing on cell signaling in cancer processes. At that time, the U.S. Food and Drug Administration (FDA) was nearing approval for the use of the biological drug Herceptin in breast cancer with overexpression of the HER2 oncogene.
Dr. Soussan-Gutman recognized the emerging medical need for companion genomic and genetic testing to assess the genetic suitability of tumors and patients for targeted biological therapies. She understood that beyond this specific test, the medical field was on the brink of a revolution toward personalized medicine, and she identified a tremendous business opportunity in establishing a service to provide molecular diagnostic services for various types of cancer.
Our Team
Since 2019, Oncotest has been part of the Rhenium group, a leading life science company in Israel, distributing the Thermo Fisher Scientific platform in the field of molecular pathology. We provide high professional support, including a team of expert biologists with extensive experience.
Oncotest has 35 employees and is composed of several professional teams, including a scientific team, an operations team, a sales and marketing team, and a clinical team.
Our Partners
Our international partnerships allow us to bring advanced technologies, tailored solutions, and high-quality products to Israel, improving cancer treatment and enhancing patients' quality of life.
